{"product_id":"veracyte-swot-analysis","title":"Veracyte SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eVeracyte stands at the intersection of genomic diagnostics and oncology with strong IP, diversified test portfolio, and growing market adoption—yet it faces reimbursement pressures, regulatory complexity, and competition from larger diagnostics firms. Discover the complete picture behind the company’s market position with our full SWOT analysis: an in-depth, editable report with financial context and strategic takeaways for investors, analysts, and executives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Position of Decipher and Afirma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Decipher prostate test and Afirma thyroid test drive Veracyte's growth; Decipher volumes rose 27% in 2025 and Afirma remains a top revenue contributor. \u003c\/p\u003e\n\u003cp\u003eBoth tests show high clinician adoption and are embedded in NCCN and other guideline updates, strengthening Veracyte's competitive moat. \u003c\/p\u003e\n\u003cp\u003eDecipher exceeded 100,000 annual tests by end-2025, signalling its role as a standard of care and supporting recurring revenue and margin stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Financial Performance and Profitability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte reached sustained profitability in 2025, reporting full-year revenue of about 515–517 million dollars, up 16% year-over-year.\u003c\/p\u003e\n\u003cp\u003eAdjusted EBITDA margin exceeded 25% for the year, showing marked operational efficiency and scalable unit economics.\u003c\/p\u003e\n\u003cp\u003eCash and equivalents near 300 million dollars bolster R\u0026amp;D funding and optionality for strategic acquisitions, reducing financing risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Value Evidence Generation Engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte’s Diagnostics Platform pairs broad genomic datasets with AI\/bioinformatics, driving an evidence engine that supported 2024 revenue of $232.8M and payer coverage for \u0026gt;90% of commercial lives; this data focus helped secure durable reimbursement and high clinical utility across thyroid, lung, and prostate tests.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Expansion into the Patient Journey\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte broadened its care footprint by adding the Decipher metastatic prostate cancer indication in 2025, extending testing from diagnosis into treatment and monitoring phases.\u003c\/p\u003e\n\u003cp\u003eThis expansion lifts total addressable market—Veracyte cited a prostate oncology TAM increase to roughly $1.2 billion in 2025—and strengthens provider ties by embedding tests at multiple decision points.\u003c\/p\u003e\n\u003cp\u003eServing patients across the journey diversifies revenue in oncology, reducing single-product reliance and supporting more stable growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDecipher metastatic launch: 2025\u003c\/li\u003e\n\u003cli\u003eEstimated prostate oncology TAM: $1.2B (2025)\u003c\/li\u003e\n\u003cli\u003eStronger provider integration across care stages\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScalable Laboratory Operations and Cost Efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn 2025 Veracyte shifted Afirma production to newer equipment and began using NovaSeq X sequencing, cutting per-test cost and targeting a \u0026gt;10% reduction in cost-of-goods-sold (COGS) over 2024 levels, which should widen gross margins and lift long-term profitability.\u003c\/p\u003e\n\u003cp\u003eThis scalable setup lets lab capacity grow 30–50% without matching opex increases, supporting volume-driven margin expansion and enabling handling of rising test demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025: NovaSeq X adoption; \u0026gt;10% COGS target vs 2024\u003c\/li\u003e\n\u003cli\u003eCapacity rise: +30–50% without proportional opex\u003c\/li\u003e\n\u003cli\u003eExpected: sustained gross-margin improvement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecipher \u0026amp; Afirma propel 2025: $515–517M revenue, \u0026gt;25% EBITDA, \u0026gt;100k tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDecipher and Afirma drive growth, with Decipher \u0026gt;100,000 tests in 2025 and Afirma a top revenue source; 2025 revenue ~$515–517M, adjusted EBITDA \u0026gt;25%, cash ≈$300M. Decipher metastatic launch (2025) raised prostate TAM to ~$1.2B; payer coverage \u0026gt;90% and NovaSeq X adoption cut COGS target \u0026gt;10% and raised lab capacity 30–50%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$515–517M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA margin\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e≈$300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecipher tests\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProstate TAM\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer coverage\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS target vs 2024\u003c\/td\u003e\n\u003ctd\u003e−\u0026gt;10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity uplift\u003c\/td\u003e\n\u003ctd\u003e30–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Veracyte, highlighting its diagnostic innovation and partnerships as strengths, operational and reimbursement risks as weaknesses, expansion and product pipeline opportunities, and competitive, regulatory, and market-adoption threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCompact Veracyte SWOT matrix condenses diagnostic strengths, market opportunities, and risk areas into a visual summary for swift strategic alignment and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue Concentration in Core Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpdespite expanding its portfolio veracyte still relies on decipher and afirma for roughly of revenue diagnostic tests drove lab in contributed about cash flow prostate thyroid diagnostics. this dependence raises exposure to reimbursement cuts guideline shifts or rivals a reduction could cut overall by lung bladder programs are progressing but as q4 they generate under lack comparable commercial scale.\u003e\n\u003c\/pdespite\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Timeline Delays for Envisia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnvisia's genomic classifier launch for interstitial lung disease was paused after FDA and Medicare coverage hurdles, cutting projected pulmonology revenue by an estimated $15–25m in 2024–25 and delaying scale-up expected by management in late 2025.\u003c\/p\u003e\n\u003cp\u003eThese regulatory and reimbursement delays increase execution risk, may push cash-pay adoption down from a modeled 30% to under 10%, and give rivals time to capture diagnostic share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRestructuring Challenges in European Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe 2025 bankruptcy of Veracyte SAS after parent funding stopped highlights scaling issues in Europe; the subsidiary filed in March 2025 after burning roughly €6.5M in 2024 operations, per company filings. Management says no material long-term revenue impact, but restructuring likely pushes European IVD launches beyond 2026 targets and may cut ~30% of regional headcount. Adapting a U.S. CLIA lab model to varied EU regulatory and reimbursement rules remains a clear operational weakness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Valuation and Execution Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpas of late veracyte trades at a premium fiscal consensus eps any miss on aggressive revenue targets would amplify downside risk and stock volatility.\u003e\n\u003cpany delay in launches like truemrd or a quarterly earnings miss could trigger\u003e15–25% intraday swings, given tight expectations and 40%+ revenue growth baked into 2026 guidance.\n\u003cpflawless execution of the product roadmap is needed to justify current p otherwise valuation compression likely.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePremium P\/E ~35x (2026 consensus)\u003c\/li\u003e\n\u003cli\u003eMarket expects ~40% revenue growth (2026)\u003c\/li\u003e\n\u003cli\u003ePotential 15–25% intraday swings on misses\u003c\/li\u003e\n\u003cli\u003eTrueMRD launch delays raise execution risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pflawless\u003e\u003c\/pany\u003e\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Competition from Genomic Giants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte faces intense competition from Exact Sciences, Guardant Health, and Myriad Genetics, each with larger salesforces and broader portfolios that can bundle services and exploit hospital contracts; Exact Sciences reported 2024 revenue of $4.1B, Guardant $1.1B, Myriad $514M, versus Veracyte’s $452M (FY 2024).\u003c\/p\u003e\n\u003cp\u003eTo keep pace Veracyte must sustain high R\u0026amp;D spend—R\u0026amp;D was ~17% of revenue in 2024—pressuring margins if revenue growth lags innovation costs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge rivals: Exact $4.1B, Guardant $1.1B, Myriad $514M, Veracyte $452M (2024)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D intensity: ~17% of Veracyte revenue (2024)\u003c\/li\u003e\n\u003cli\u003eRisk: margin pressure if sales growth \u0026lt; R\u0026amp;D growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte: Heavy Decipher\/Afirma Reliance, EU Setbacks \u0026amp; Execution Risk at 35x P\/E\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpveracyte depends on decipher for revenue afirma in faces eu scaling failures sas bankruptcy mar burn paused envisia launch cutting high r of and premium p raise execution valuation risk.\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecipher (2024)\u003c\/td\u003e\n\u003ctd\u003e$236M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma (2024)\u003c\/td\u003e\n\u003ctd\u003e$85M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVeracyte revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$452M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D intensity (2024)\u003c\/td\u003e\n\u003ctd\u003e17%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVeracyte SAS burn (2024)\u003c\/td\u003e\n\u003ctd\u003e€6.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2026 P\/E\u003c\/td\u003e\n\u003ctd\u003e~35x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pveracyte\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eVeracyte SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the file shown is the real, downloadable analysis included in your purchase. Buy now to unlock the complete, editable version with full, structured insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752274669945,"sku":"veracyte-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/veracyte-swot-analysis.png?v=1772239041","url":"https:\/\/matrixbcg.com\/products\/veracyte-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}